Compare Stocks → Global crypto currency reset (41 major banks signed up) (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CYADNASDAQ:MBIOOTCMKTS:NWBONASDAQ:OBSVNASDAQ:SBBP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYADCelyad Oncology$0.60$0.67$0.46▼$3.07$15.91MN/AN/A3,009 shsMBIOMustang Bio$0.35-2.8%$0.96$0.33▼$8.17$3.74M1.58177,655 shs123,283 shsNWBONorthwest Biotherapeutics$0.46-2.1%$0.54$0.40▼$1.09$553.95M-0.681.73 million shs1.17 million shsOBSVObsEva$0.01$0.02$0.08▼$2.14$390K0.688.94 million shs8,190 shsSBBPStrongbridge Biopharma$2.00$2.09$1.85▼$4.26$135.66M1.58866,464 shs684,684 shsThe Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYADCelyad Oncology0.00%0.00%0.00%0.00%-15.71%MBIOMustang Bio-2.67%-8.83%-63.53%-75.35%-90.91%NWBONorthwest Biotherapeutics-2.54%-8.18%-10.31%-22.59%-8.00%OBSVObsEva0.00%0.00%-50.00%-90.91%-94.05%SBBPStrongbridge Biopharma0.00%0.00%0.00%0.00%0.00%Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.Click here to find out that this 8,788% cryptocurrency is.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYADCelyad OncologyN/AN/AN/AN/AN/AN/AN/AN/AMBIOMustang Bio2.0139 of 5 stars3.55.00.00.02.40.00.0NWBONorthwest BiotherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/AN/AN/AN/ASBBPStrongbridge BiopharmaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYADCelyad OncologyN/AN/AN/AN/AMBIOMustang Bio3.00Buy$17.254,827.16% UpsideNWBONorthwest BiotherapeuticsN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/ASBBPStrongbridge BiopharmaN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYADCelyad Oncology$110K144.65N/AN/A$0.20 per share3.00MBIOMustang BioN/AN/AN/AN/A$0.01 per shareN/ANWBONorthwest Biotherapeutics$1.93M287.02N/AN/A($0.06) per share-7.67OBSVObsEva$20.11M0.02N/AN/A$0.41 per share0.01SBBPStrongbridge Biopharma$30.73M4.41N/AN/A$0.98 per share2.04Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYADCelyad Oncology-$9.14MN/A0.00∞N/AN/AN/AN/AN/AMBIOMustang Bio-$51.60M-$6.00N/A∞N/AN/A-433.08%-146.39%5/10/2024 (Estimated)NWBONorthwest Biotherapeutics-$62.60M-$0.06N/A∞N/A-3,240.11%N/A-207.51%5/8/2024 (Estimated)OBSVObsEva-$58.38M-$0.92N/A∞N/AN/A-416.36%-92.01%N/ASBBPStrongbridge Biopharma-$45.08M-$0.78N/AN/AN/A-115.67%-66.82%-36.21%N/ALatest SBBP, OBSV, CYAD, NWBO, and MBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/11/2024Q4 2023MBIOMustang Bio-$1.68-$0.71+$0.97-$0.71N/AN/A3/5/2024Q4 2023NWBONorthwest BiotherapeuticsN/A-$0.02-$0.02-$0.02N/A$0.45 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYADCelyad OncologyN/AN/AN/AN/AN/AMBIOMustang BioN/AN/AN/AN/AN/ANWBONorthwest BiotherapeuticsN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/ASBBPStrongbridge BiopharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYADCelyad OncologyN/AN/AN/AMBIOMustang BioN/A0.740.74NWBONorthwest BiotherapeuticsN/A0.090.09OBSVObsEvaN/A0.610.61SBBPStrongbridge Biopharma0.383.002.95OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYADCelyad OncologyN/AMBIOMustang Bio9.95%NWBONorthwest Biotherapeutics0.04%OBSVObsEva17.52%SBBPStrongbridge Biopharma52.03%Insider OwnershipCompanyInsider OwnershipCYADCelyad Oncology0.94%MBIOMustang Bio2.10%NWBONorthwest Biotherapeutics13.90%OBSVObsEva14.40%SBBPStrongbridge Biopharma5.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCYADCelyad Oncology9526.52 million26.28 millionNot OptionableMBIOMustang Bio8010.39 million10.17 millionNot OptionableNWBONorthwest Biotherapeutics251.20 billion1.04 billionNot OptionableOBSVObsEva4877.97 million66.74 millionNot OptionableSBBPStrongbridge Biopharma7267.83 millionN/AOptionableSBBP, OBSV, CYAD, NWBO, and MBIO HeadlinesSourceHeadlineRising Investment in Patient Support Drives a Greater Biopharma Focus on Measurementfiercepharma.com - March 5 at 7:51 AMMatinas BioPharma Holdings Inc (MTNB)investing.com - February 10 at 12:33 PMLytix Biopharma As Share Price (LYTIX.OL)lse.co.uk - November 15 at 2:21 AMAmbrx Biopharma Inc AMAMmorningstar.com - November 4 at 7:36 PMBiopharma’s rapid transition to omnichannel marketingpharmaphorum.com - September 11 at 9:18 AMHILS Hillstream BioPharma, Inc.seekingalpha.com - August 19 at 3:55 PMABUS - Arbutus Biopharma Corporationfinance.yahoo.com - July 1 at 12:38 PMThe Nominees for Best Biopharma CEO of 2015 Are...thestreet.com - April 25 at 8:23 AMDay One Biopharma Shares Rise 13% After Positive Topline Results for Tovorafenibmarketwatch.com - January 11 at 9:43 PMBiopharma Soars to the Computational Cloudsgenengnews.com - October 9 at 12:47 PMAccord BioPharma Partners with StoryMD to Deliver Advanced Prostate Cancer Educational Content to Clinicians and Patientsmarkets.businessinsider.com - September 22 at 10:04 AMStrongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by ...apnews.com - September 23 at 5:49 PMStrongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by Xeris Pharmaceuticals, Inc.finance.yahoo.com - September 23 at 5:49 PMPress Release: Xeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge Biopharmasharecast.com - September 14 at 5:56 PMXeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge Biopharmastockhouse.com - September 14 at 5:56 PMStrongbridge Biopharma plc Announces Shareholder Approval of Proposed Acquisition by Xeris ...apnews.com - September 9 at 12:31 PMLeading Independent Proxy Advisory Firm ISS Recommends Strongbridge Biopharma plc Shareholders ...apnews.com - August 31 at 7:54 AMSecond Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote "FOR" the Transaction With Xeristmcnet.com - August 31 at 7:54 AMSecond Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote “FOR” the Transaction With Xerisfinance.yahoo.com - August 31 at 7:54 AMStrongbridge Biopharma plc (NASDAQ: SBBP) Have Dropped -20.16% YTD, What Will Happen Nextmarketingsentinel.com - August 14 at 7:50 AMStrongbridge Biopharma: Q2 Earnings Snapshotsfgate.com - August 5 at 8:43 AMStrongbridge Biopharma plc Reports Second Quarter 2021 Financial Results and Provides Corporate Updatefinance.yahoo.com - August 5 at 8:43 AMStrongbridge Biopharma plc Announces Commencement of Mailing of Proxy Statementfinance.yahoo.com - August 2 at 9:34 AMStrongbridge Biopharma plc (NASDAQ:SBBP) Shares Plunges -8.08% In A Week – But Can It Keep Rising?marketingsentinel.com - July 31 at 9:50 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCelyad OncologyNASDAQ:CYADCelyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.Mustang BioNASDAQ:MBIOMustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.Northwest BiotherapeuticsOTCMKTS:NWBONorthwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.ObsEvaNASDAQ:OBSVObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.Strongbridge BiopharmaNASDAQ:SBBPStrongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded in 1996 and is headquartered in Trevose, PA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.